 Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date more than 250,000 coronavirus test samples at its San Diego lab What Biocept does: Biocept Inc NASDAQ:BIOC is a molecular diagnostics company focused on changing the way physicians examine blood in their patients with cancer. The San Diego-based company sells CEE-Sure blood collection tubes and has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells CTCs and cell-free circulating tumor DNA ctDNA. 